These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 16417938)

  • 41. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile.
    Ríos M; Delgado E; Pérez-Alvarez L; Fernández J; Gálvez P; de Parga EV; Yung V; Thomson MM; Nájera R
    J Med Virol; 2007 Jun; 79(6):647-56. PubMed ID: 17457921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].
    Rodriguez-Escudero MJ; Prada de Medio E; Rosa Herranz C; Martinez Medina MC; Franquelo Gutierrez R
    Rev Esp Quimioter; 2007 Jun; 20(2):203-5. PubMed ID: 17893756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
    Varella RB; Ferreira SB; de Castro MB; Zalis MG; Tavares MD
    J Med Virol; 2007 Aug; 79(8):1033-9. PubMed ID: 17596836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
    Nadembega WM; Giannella S; Simpore J; Ceccherini-Silberstein F; Pietra V; Bertoli A; Pignatelli S; Bellocchi MC; Nikiema JB; Cappelli G; Bere A; Colizzi V; Perno CP; Musumeci S
    J Med Virol; 2006 Nov; 78(11):1385-91. PubMed ID: 16998878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.
    Vergne L; Diagbouga S; Kouanfack C; Aghokeng A; Butel C; Laurent C; Noumssi N; Tardy M; Sawadogo A; Drabo J; Hien H; Zekeng L; Delaporte E; Peeters M
    Antivir Ther; 2006; 11(5):575-9. PubMed ID: 16964825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities.
    Sullivan PS; Buskin SE; Turner JH; Cheingsong R; Saekhou A; Kalish ML; Jones JL; Respess R; Kovacs A; Heneine W
    Int J STD AIDS; 2002 Aug; 13(8):554-8. PubMed ID: 12194739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moderate prevalence of transmitted drug resistance and interiorization of HIV type 1 subtype C in the inland North State of Tocantins, Brazil.
    Carvalho BC; Cardoso LP; Damasceno S; Stefani MM
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1081-7. PubMed ID: 21417758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    Colson P; Henry M; Tivoli N; Gallais H; Gastaut JA; Moreau J; Tamalet C
    J Med Virol; 2005 Mar; 75(3):381-90. PubMed ID: 15648062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Genetic characteristics of HIV-1 primary drug resistance-associated mutations in treatment-naive individuals in Liaoning province, 2004-2008].
    Wu SH; Lu CM; Jiang FX; E S; Ma N; Liang XW; Gai XQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Nov; 43(11):951-5. PubMed ID: 20137514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
    Valle-Bahena OM; Ramos-Jiménez J; Ortiz-López R; Revol A; Lugo-Trampe A; Barrera-Saldaña HA; Rojas-Martínez A
    Arch Med Res; 2006 Nov; 37(8):1022-7. PubMed ID: 17045121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
    Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
    J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.
    Vergne L; Snoeck J; Aghokeng A; Maes B; Valea D; Delaporte E; Vandamme AM; Peeters M; Van Laethem K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):53-62. PubMed ID: 16420597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
    De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia.
    Balode D; Westman M; Kolupajeva T; Rozentale B; Albert J
    J Med Virol; 2010 Dec; 82(12):2013-8. PubMed ID: 20981787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
    Van Vaerenbergh K; Debaisieux L; De Cabooter N; Declercq C; Desmet K; Fransen K; Maes B; Marissens D; Miller K; Muyldermans G; Sprecher S; Stuyver L; Vaira D; Verhofstede C; Zissis G; Van Ranst M; De Clercq E; Desmyter J; Vandamme AM
    Antivir Ther; 2001 Mar; 6(1):63-70. PubMed ID: 11417763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.